Geriatric Research, Education and Clinical Center, V A Boston Healthcare System, Department of Neurology, Harvard Medical School, Boston, MA, USA.
Clin Interv Aging. 2010 Feb 2;5:1-6.
An extended release form of the cholinesterase inhibitor (ChEI) drug galantamine (galantamine-ER) was developed, chiefly to increase adherence to medication regimes in patients with mild-to-moderate Alzheimer's disease (AD). Except for predicted differences in (C(max)) and t(max), comparable doses of once daily galantamine-ER and regular, immediate release galantamine, (galantamine-IR), are pharmacologically equivalent. A 24-week randomized, double-blind, placebo-and active-controlled, multicenter phase III trial, which compared galantamine-IR, galantamine-ER and placebo in subjects with mild to moderate AD (mini-mental state examination [MMSE] score range, 10 to 24) showed that both formulations of galantamine were significantly better than placebo in terms of cognition, although not with regard to global change. There was no difference in drug-related adverse events between galantamine-ER and galantamine-IR. Since its release onto the market galantamine-ER has enjoyed wide popularity and a recent surveillance study suggests that it has the highest 1-year persistence rate of all the ChEIs.
一种长效的胆碱酯酶抑制剂（ChEI）药物加兰他敏（galantamine-ER）被开发出来，主要是为了提高轻度至中度阿尔茨海默病（AD）患者对药物治疗方案的依从性。除了（C(max)）和 t(max）的预期差异外，每日一次的 galantamine-ER 和常规的即刻释放加兰他敏（galantamine-IR）的等效剂量在药理学上是等效的。一项为期 24 周的随机、双盲、安慰剂和阳性对照、多中心 III 期试验比较了 galantamine-IR、galantamine-ER 和安慰剂在轻度至中度 AD 患者（迷你精神状态检查 [MMSE] 评分范围为 10 至 24）中，两种加兰他敏制剂在认知方面均显著优于安慰剂，尽管在整体变化方面没有差异。galantamine-ER 和 galantamine-IR 之间药物相关不良事件无差异。自上市以来，galantamine-ER 已广受欢迎，最近的一项监测研究表明，它是所有 ChEIs 中 1 年持续率最高的药物。
